Brief: PhaseBio Presents Data From Phase 1B/2A Trial Of Pemziviptadil To Treat Pulmonary Arterial Hypertension At Pulmonary Vascular Research Institute Virtual World Congress

PhaseBio Pharmaceuticals

27/01/2021 21:47

Jan 27 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO PRESENTS DATA FROM PHASE 1B/2A TRIAL OF
PEMZIVIPTADIL
FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION AT 15TH
PULMONARY VASCULAR RESEARCH INSTITUTE VIRTUAL WORLD CONGRESS
    * PHASEBIO - NEW DATA FOR PEMZIVIPTADIL SUPPORT CONTINUED
EVALUATION AS A POTENTIAL NOVEL THERAPY FOR ADULTS WITH
PULMONARY ARTERIAL HYPERTENSION

Source text for Eikon:  ID:nBwgKK74a 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))